Sun Pharmaceutical to Acquire Organon for $11.75 Billion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Source: Newsfilter
- Acquisition Scale: Sun Pharmaceutical Industries is set to acquire Organon in an all-cash deal valued at approximately $11.75 billion, including debt, indicating the company's intent to expand its footprint in the global pharmaceutical market.
- Per Share Purchase Price: Under the agreement, Sun Pharma will buy all outstanding shares of Organon for $14.00 per share in cash, a price that reflects confidence in Organon's future growth potential.
- Market Positioning: This acquisition will grant Sun Pharma full ownership of Organon, which focuses on women's health, biosimilars, and established medicines, thereby enhancing its competitive edge in these critical sectors.
- Strategic Implications: Through this acquisition, Sun Pharma not only expands its product portfolio but also solidifies its position in the global pharmaceutical industry, particularly increasing its influence in the women's health segment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SUN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SUN
Wall Street analysts forecast SUN stock price to fall
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 68.420
Low
57.00
Averages
63.67
High
70.00
Current: 68.420
Low
57.00
Averages
63.67
High
70.00
About SUN
Sunoco LP is an energy infrastructure and fuel distribution master limited partnership operating across 32 countries and territories in North America, the Greater Caribbean, and Europe. Its midstream operations include a network of approximately 14,000 miles of pipeline and over 160 terminals. Its Fuel Distribution segment supplies motor fuel to independently operated dealer stations, distributors, commission agents and other consumers. Its Pipeline Systems segment includes an integrated pipeline and terminal network comprised of refined products, crude oil and ammonia pipelines and terminals. Through its Terminals segment, it operates four transmix processing facilities and 83 terminals. Its terminals provide storage and distribution services to support our fuel distribution business and other third-party customers. Its Refinery segment is composed of the Burnaby Refinery, which is responsible for the refining of fuel products and engaged in renewable business activities.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sun Pharma's Chair: Partnership with Organon Opens Doors for Product Launches in New Markets
India's Sun Pharma Chair: The chair of Sun Pharmaceutical Industries has announced a deal with Organo, which presents new opportunities for product launches.
Geographic Expansion: This partnership allows Sun Pharma to explore product launches in geographic areas where it currently has no presence.
See More
Indian Stocks Set to Rebound on Monday Amid Earnings and Crude Prices
- Market Rebound Anticipation: Indian stocks are expected to open about 1% higher on Monday, with GIFT Nifty futures at 24,143.50 points, driven by buying interest in undervalued stocks following recent corrections, although overall sentiment remains subdued.
- Crude Price Impact: Brent crude is trading at approximately $107 per barrel, as disruptions in Middle Eastern energy exports due to the Iran war crisis raise concerns about global economic slowdown and inflation, impacting investor sentiment.
- Earnings Reports Focus: Quarterly earnings from Reliance Industries and Axis Bank will be in focus, with Reliance missing profit expectations due to rising costs and supply disruptions, while Axis Bank faces pressure from lower treasury income and higher provisions.
- Foreign Investment Trends: Foreign portfolio investors have been net sellers of Indian stocks for the fifth consecutive session, while domestic institutional investors continue to buy, indicating a divergence in market liquidity dynamics.
See More
Sun Pharmaceutical to Acquire Organon for $11.75 Billion
- Acquisition Scale: Sun Pharmaceutical Industries is set to acquire Organon in an all-cash deal valued at approximately $11.75 billion, including debt, indicating the company's intent to expand its footprint in the global pharmaceutical market.
- Per Share Purchase Price: Under the agreement, Sun Pharma will buy all outstanding shares of Organon for $14.00 per share in cash, a price that reflects confidence in Organon's future growth potential.
- Market Positioning: This acquisition will grant Sun Pharma full ownership of Organon, which focuses on women's health, biosimilars, and established medicines, thereby enhancing its competitive edge in these critical sectors.
- Strategic Implications: Through this acquisition, Sun Pharma not only expands its product portfolio but also solidifies its position in the global pharmaceutical industry, particularly increasing its influence in the women's health segment.
See More
Sunoco LP Declares 6.2% Increase in Quarterly Dividend
- Dividend Increase: Sunoco LP has declared a quarterly dividend of $0.9899 per share, representing a 6.2% increase from the previous dividend of $0.9317, indicating ongoing improvements in cash flow and profitability, which is expected to boost investor confidence and attract more capital inflow.
- Yield Advantage: The forward yield of 6.07% not only provides shareholders with a substantial return but also enhances the company's attractiveness in the competitive energy market, further solidifying its market position.
- Payment Schedule: The dividend will be payable on May 20, with a record date of May 8 and an ex-dividend date also on May 8, ensuring that shareholders receive their earnings promptly, reflecting the company's commitment to shareholder interests.
- Debt Financing Plan: Sunoco LP plans to issue $1.2 billion in senior notes due in 2031 and 2034, a financing move that will provide additional capital support for the company's future expansion and investment strategies.
See More
Iran: No Agreement Reached for Next Round of Talks with the United States
Iran's Stance on Talks: Iran has not agreed to hold the next round of talks with the United States, as reported by Tasnim News Agency.
Trump's Expectations: Former U.S. President Trump mentioned that U.S.-Iran negotiation representatives may meet this weekend, anticipating a final agreement to end the war.
Timeline for Agreement: Trump expressed confidence that an agreement could be reached within one or two days.
Context of Negotiations: The discussions are part of ongoing efforts to resolve tensions between the U.S. and Iran.
See More
Sunoco to Release Q1 2026 Financial Results
- Earnings Release Announcement: Sunoco LP and SunocoCorp LLC announced they will release their Q1 2026 financial and operating results before market open on May 5, 2026, indicating a commitment to transparency and investor communication.
- Conference Call Details: Management will hold a conference call on the same day at 9:00 a.m. Central Time (10:00 a.m. Eastern Time) to discuss the results, reflecting the company's intention to enhance investor confidence through direct engagement.
- Webcast Access: The conference call will be broadcast live via an internet webcast on Sunoco LP's website, requiring investors to log in at least 10 minutes in advance, showcasing the company's use of technology to improve information dissemination efficiency.
- Company Background: Sunoco LP is a leading energy infrastructure and fuel distribution master limited partnership operating across North America, the Greater Caribbean, and Europe, with approximately 14,000 miles of pipeline and over 160 terminals, underscoring its significant position in the energy sector.
See More
Sun Pharma's Chair: Partnership with Organon Opens Doors for Product Launches in New Markets
India's Sun Pharma Chair: The chair of Sun Pharmaceutical Industries has announced a deal with Organo, which presents new opportunities for product launches.
Geographic Expansion: This partnership allows Sun Pharma to explore product launches in geographic areas where it currently has no presence.
See More
Indian Stocks Set to Rebound on Monday Amid Earnings and Crude Prices
- Market Rebound Anticipation: Indian stocks are expected to open about 1% higher on Monday, with GIFT Nifty futures at 24,143.50 points, driven by buying interest in undervalued stocks following recent corrections, although overall sentiment remains subdued.
- Crude Price Impact: Brent crude is trading at approximately $107 per barrel, as disruptions in Middle Eastern energy exports due to the Iran war crisis raise concerns about global economic slowdown and inflation, impacting investor sentiment.
- Earnings Reports Focus: Quarterly earnings from Reliance Industries and Axis Bank will be in focus, with Reliance missing profit expectations due to rising costs and supply disruptions, while Axis Bank faces pressure from lower treasury income and higher provisions.
- Foreign Investment Trends: Foreign portfolio investors have been net sellers of Indian stocks for the fifth consecutive session, while domestic institutional investors continue to buy, indicating a divergence in market liquidity dynamics.
See More
Sun Pharmaceutical to Acquire Organon for $11.75 Billion
- Acquisition Scale: Sun Pharmaceutical Industries is set to acquire Organon in an all-cash deal valued at approximately $11.75 billion, including debt, indicating the company's intent to expand its footprint in the global pharmaceutical market.
- Per Share Purchase Price: Under the agreement, Sun Pharma will buy all outstanding shares of Organon for $14.00 per share in cash, a price that reflects confidence in Organon's future growth potential.
- Market Positioning: This acquisition will grant Sun Pharma full ownership of Organon, which focuses on women's health, biosimilars, and established medicines, thereby enhancing its competitive edge in these critical sectors.
- Strategic Implications: Through this acquisition, Sun Pharma not only expands its product portfolio but also solidifies its position in the global pharmaceutical industry, particularly increasing its influence in the women's health segment.
See More
Sunoco LP Declares 6.2% Increase in Quarterly Dividend
- Dividend Increase: Sunoco LP has declared a quarterly dividend of $0.9899 per share, representing a 6.2% increase from the previous dividend of $0.9317, indicating ongoing improvements in cash flow and profitability, which is expected to boost investor confidence and attract more capital inflow.
- Yield Advantage: The forward yield of 6.07% not only provides shareholders with a substantial return but also enhances the company's attractiveness in the competitive energy market, further solidifying its market position.
- Payment Schedule: The dividend will be payable on May 20, with a record date of May 8 and an ex-dividend date also on May 8, ensuring that shareholders receive their earnings promptly, reflecting the company's commitment to shareholder interests.
- Debt Financing Plan: Sunoco LP plans to issue $1.2 billion in senior notes due in 2031 and 2034, a financing move that will provide additional capital support for the company's future expansion and investment strategies.
See More
Iran: No Agreement Reached for Next Round of Talks with the United States
Iran's Stance on Talks: Iran has not agreed to hold the next round of talks with the United States, as reported by Tasnim News Agency.
Trump's Expectations: Former U.S. President Trump mentioned that U.S.-Iran negotiation representatives may meet this weekend, anticipating a final agreement to end the war.
Timeline for Agreement: Trump expressed confidence that an agreement could be reached within one or two days.
Context of Negotiations: The discussions are part of ongoing efforts to resolve tensions between the U.S. and Iran.
See More
Sunoco to Release Q1 2026 Financial Results
- Earnings Release Announcement: Sunoco LP and SunocoCorp LLC announced they will release their Q1 2026 financial and operating results before market open on May 5, 2026, indicating a commitment to transparency and investor communication.
- Conference Call Details: Management will hold a conference call on the same day at 9:00 a.m. Central Time (10:00 a.m. Eastern Time) to discuss the results, reflecting the company's intention to enhance investor confidence through direct engagement.
- Webcast Access: The conference call will be broadcast live via an internet webcast on Sunoco LP's website, requiring investors to log in at least 10 minutes in advance, showcasing the company's use of technology to improve information dissemination efficiency.
- Company Background: Sunoco LP is a leading energy infrastructure and fuel distribution master limited partnership operating across North America, the Greater Caribbean, and Europe, with approximately 14,000 miles of pipeline and over 160 terminals, underscoring its significant position in the energy sector.
See More
